MRDx® BCR-ABL Test
The FDA Authorized Test for TFR Initiation and Monitoring
The MRDx® BCR-ABL Test is a companion diagnostic for Chronic Myeloid Leukemia (CML) patients in the chronic phase (CP) being treated with Tasigna®* who may be candidates for treatment discontinuation and monitoring of treatment-free remission (TFR). Read our Press Release.
Monitoring of TFR requires the ability to accurately measure BCR-ABL transcripts to a depth, classified as MR4.5 (BCR-ABL/ABL ≤0.0032% International Scale).
The MRDx BCR-ABL Test has consistently demonstrated sensitivity in ENESTfreedom and ENESTop clinical studies to MR4.5. The MRDx BCR-ABL Test is based on real-time quantitative PCR and measures BCR-ABL transcripts (e13a2/b2a2 and/or e14a2/b3a2) from peripheral blood specimens in CMP-CP Ph+ patients.
GET MRDx NOW
The MRDx BCR-ABL Test can be ordered directly through MolecularMD. Additional reference laboratories will offer the test once it gets established within their systems.
*Tasigna is a registered trademark of Novartis AG